PixarBio (PixarBio) Change In Receivables : $0.00 Mil (TTM As of Sep. 2016)

View and export this data going back to 2016. Start your Free Trial

What is PixarBio Change In Receivables?

PixarBio's change in receivables for the quarter that ended in Sep. 2016 was $0.00 Mil. It means PixarBio's Accounts Receivable stayed the same from Jun. 2016 to Sep. 2016 .

PixarBio's change in receivables for the fiscal year that ended in Dec. 2015 was $0.00 Mil. It means PixarBio's Accounts Receivable stayed the same from Dec. 2014 to Dec. 2015 .

PixarBio's Accounts Receivable for the quarter that ended in Sep. 2016 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. PixarBio's Days Sales Outstanding for the three months ended in Sep. 2016 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. PixarBio's liquidation value for the three months ended in Sep. 2016 was $-0.00 Mil.

PixarBio Change In Receivables Historical Data

The historical data trend for PixarBio's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PixarBio Change In Receivables Chart

PixarBio Annual Data

Trend

Dec14

Dec15

Change In Receivables

PixarBio Quarterly Data
	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Change In Receivables	Get a 7-Day Free Trial					-	-	-	-	-

PixarBio Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

PixarBio (GREY:PXRB) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

PixarBio's Days Sales Outstanding for the quarter that ended in Sep. 2016 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0.015	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, PixarBio's accounts receivable are only considered to be worth 75% of book value:

PixarBio's liquidation value for the quarter that ended in Sep. 2016 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.004	-	0.005	+	0.75 * 0	+	0.5 * 0
=	-0.00

PixarBio Change In Receivables Related Terms

Thank you for viewing the detailed overview of PixarBio's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

PixarBio (PixarBio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PixarBio Corp (GREY:PXRB) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Boston Avenue, Suite 1875, Medford, MA, USA, 02155

Website

https://www.pixarbio.com

PixarBio Corp is a specialty pharmaceutical company focused on preclinical and clinical commercial development of therapeutic drug delivery systems for post-operative pain. The company's lead clinical candidate, NeuroRelease is a non-opioid / non-opiate preclinical stage product intended for the treatment of surgical pain, with planned future indications for chronic pain. NeuroRelease blocks nociceptive and neuropathic pain signals arising from temperature and pressure stimuli without affecting motor function, which is intended to allow for effective treatment without delaying post-surgical physical therapy.